XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment

The following table provides the operating expenses of our clinical stage drug development segment (rounded to the nearest $00):

 

   March 31,   March 31, 
   2025   2024 
Clinical Study Expense  $7,960,600   $3,172,600 
Other Research Expense   1,831,000    7,066,900 
Manufacturing and Drug Storage Expense   155,600    292,500 
Pre-clinical Expense   
-
    33,700 
Compensation Expense   933,500    1,040,300 
Stock-based Compensation Expense   1,070,300    1,699,300 
Total Research and Development Expense  $11,951,000   $13,305,300